Lexaria says it filed three patent applications and is pitching its formulations as an alternative to SNAC, the absorption enhancer in Novo's oral semaglutide.
Recap by typeshit. Full story at guardonline.com.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
A short explainer for newcomers placing Ozempic, Wegovy, Mounjaro and Zepbound in the same molecule family that health and longevity circles keep discussing.
Dr Morse claims the drug's base chain is 39 amino acids and that two added side chains push it past the 40 amino acid biologic threshold. His take, not an FDA finding.
Loading…